文献速递神经核医学

IDEAS研究中淀粉样蛋白PET专家判读与本地临床判读的一致性比较

Comparison of Expert Reads Versus Local Clinical Reads of Amyloid PET Scans in the IDEAS Study.
PubMed 文献 · J Nucl Med · 2026-09-10

IDEAS研究纳入超过18,000例本地临床淀粉样蛋白PET判读,选取每种FDA批准示踪剂各500例扫描交由3人专家小组盲法判读。本地与专家多数判读一致性良好(κ=0.76;95%CI 0.73-0.80),阳性扫描一致率86.6%、阴性91.5%,且不随示踪剂显著变化。本地判读者信心低与一致性降低相关(P<0.001)。

要点

  • 本地临床判读与3人专家小组多数判读一致性良好,κ=0.76(95%CI 0.73-0.80)。
  • 阳性扫描一致率86.6%(790/912),阴性扫描一致率91.5%(535/585)。
  • 本地判读者信心低与一致性降低相关(P<0.001)。

核心结论

  • 本地判读者与3人专家小组多数评估之间一致性良好,淀粉样蛋白PET视觉判读可在真实临床环境中高可靠性完成。

研究设计与样本

  • 从IDEAS研究中选取代表性淀粉样蛋白PET扫描子集,每种FDA批准示踪剂(18F-florbetaben、18F-florbetapir、18F-flutemetamol)各500例,由厂商选定的3人专家小组(每种示踪剂1组)回顾性盲法视觉判读。
  • 子集按参与者年龄、认知障碍程度(轻度认知障碍 vs 痴呆)、本地判读阳性或阴性及PET机构类型分层以匹配总体研究频率。

主要发现

  • 专家小组共判读1497例扫描,参与者中位年龄75岁(范围65-96岁),女性51.4%,轻度认知障碍60.5%。
  • 本地判读者将60.9%的扫描判为阳性、39.1%判为阴性。
  • 所有示踪剂合并,专家多数判读与本地判读一致性良好(κ=0.76;95%CI 0.73-0.80),阳性扫描一致率86.6%(790/912),阴性扫描一致率91.5%(535/585)。
  • 一致性在不同PET示踪剂间无显著差异(κ=0.73-0.78)。
  • 单个专家与本地判读者之间一致性亦良好(两两κ=0.61-0.78),专家读数组内一致性同样高(κ=0.79;95%CI 0.77-0.81)。

关键数值与推荐

  • 专家判读者使用示踪剂特异性标准进行视觉判读,对临床和人口学数据盲法。
  • 采用Cohen κ评估本地判读与专家小组多数判读之间的一致性,采用Fleiss κ测量专家判读者之间的总体一致性。

临床怎么用

  • 在真实临床环境中,本地放射科医生和核医学医生对淀粉样蛋白PET的视觉判读与专家小组多数判读具有良好一致性,支持其临床可靠性。
  • 本地判读者信心低时与专家判读一致性下降,提示对此类病例可考虑复核或专家会诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Amyloid-targeting therapies and growing reimbursement are expected to increase the clinical use of amyloid PET. The Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study captured more than 18,000 clinical scan interpretations from local radiologists and nuclear medicine physicians in the United States. This study aimed to evaluate the reliability of these interpretations by comparing local clinical reads of a representative sample of IDEAS scans to retrospective majority interpretations by expert readers. Methods: A representative subset of amyloid PET scans from the IDEAS study, 500 performed with each of the Food and Drug Administration-approved tracers (18F-florbetaben, 18F-florbetapir, 18F-flutemetamol) and previously interpreted by local readers, was assigned to vendor-selected panels of 3 expert readers (1 panel per tracer). The scan subset was stratified to match the overall study frequencies by participant age, level of cognitive impairment (mild cognitive impairment vs. dementia), positive or negative local interpretation, and PET facility type. Expert readers performed visual interpretations using tracer-specific criteria, blinded to clinical and demographic data. Cohen κ assessed agreement between local reads and the majority expert panel reads, and Fleiss κ measured overall agreement among expert readers. Results: Expert panels interpreted 1497 scans. Participants were a median age of 75 y (range, 65-96 y), 51.4% were female, and 60.5% had mild cognitive impairment. Local readers interpreted 60.9% of scans as positive and 39.1% as negative. Across all radiotracers, agreement between majority expert and local reads was good (κ = 0.76; 95% CI, 0.73-0.80), with 86.6% (790/912) agreement for positive scans and 91.5% (535/585) agreement for negative scans. Agreement did not vary significantly by PET tracer (κ = 0.73-0.78). Agreement between individual experts and local readers was also good (pairwise κ = 0.61-0.78), and agreement within the expert reader group was similarly high (κ = 0.79; 95% CI, 0.77-0.81). Lower concordance between local and expert reads was associated with low local reader confidence (P < 0.001). Conclusion: We found good agreement between local readers and the majority assessment of 3-member expert panels. Visual interpretation of amyloid PET can be performed in a real-world clinical setting with high reliability.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chiotis K, Windon CC, Siegel BA, et al. Comparison of Expert Reads Versus Local Clinical Reads of Amyloid PET Scans in the IDEAS Study. J Nucl Med. 2026. PMID: 42722444. doi:10.2967/jnumed.126.272571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。